We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

The article " Moderna: A Generational Opportunity for Investors in 2025 " first appeared on MarketBeat.

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...

We recently published a list of Five Chinese Firms Dominate Friday’s Top 10 Gainers. In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against the other friday’s ...

In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock investors bought 179,268 call options on the company. This represents an increase ...

Moderna (NASDAQ:MRNA – Get Free Report)‘s stock had its “sector perform” rating reaffirmed by stock analysts at Royal Bank of Canada in a research report issued on Tuesday,Benzinga reports. They ...

Financially, Barclays noted that Moderna’s revenue declined sharply. Fourth-quarter SpikeVax sales came in at $923 million, below Barclays’ estimate of $1.087 billion, and total 2024 product revenue ...

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna (MRNA – Research Report) on February 14 and set a price target of $45.00.

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...